Article Details

FDA Approves CDx for Lorlatinib in ALK-Positive Non–Small Cell Lung Cancer

Retrieved on: 2021-03-09 19:07:21

Tags for this article:

Click the tags to see associated articles and topics

FDA Approves CDx for Lorlatinib in ALK-Positive Non–Small Cell Lung Cancer. View article details on hiswai:

Excerpt

This label expansion advances Roche's commitment to personalized healthcare by providing lung cancer patients with access to more treatment options ...

Article found on: www.targetedonc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up